Registration and Continental Breakfast
Welcome and Opening Remarks, Paul V. O'Donnell, MD, PhD, FACP
Hot Topics in Transplantation, Paul V. O'Donnell, MD, PhD, FACP, and K. Scott Baker, MD, MS
Major changes have occurred over the last decade in the field of stem cell transplantation. Stem cell sources have changed from bone marrow to peripheral blood for most disease indications in autologous transplantation. New technology, such as reduced-intensity conditioning, limits early toxicity and allows allogeneic stem cell transplantation for patients above the previous age limit. This presentation will address the changes in stem cell transplantation and review how this has impacted treatment today.
Optimal Blood/Marrow Donor Selection, Ann E. Woolfrey, MD
The goal of selecting a stem cell donor is to provide the best match between the donor and the patient (host). There are multiple options available in selecting a donor and stem cell source for allogeneic blood and marrow transplantation (BMT). The clinical problem, overall health of the donor and recipient, infectious history, and other factors are important in deciding what type of donor is selected. This presentation will discuss how the selection of a donor is a critical element contributing to the success of a BMT.
Genetic Counseling, Testing and Family History: A Genetic Counselor’s Perspective From the Trenches, Robin L. Bennett, MS, CGC, DSc (Hon)
Every day, researchers are learning more about the genetics of common diseases and how those diseases run in families. If you have an inherited disease in your family, a genetic counseling session can help you understand your personal risk or the risk for other family members. It can also help you learn what testing, surveillance, prevention strategies, or research trials may be right for your situation. This presentation will outline how genetic counselors work as part of a health care team in conjunction with specially trained doctors, social workers, nurses, medical geneticists, or other specialists to help families make informed decisions about their health.
Pathology and Precision Medicine, Thomas J. Montine, MD, PhD
Precision medicine uses molecular profiling to create diagnostic, prognostic and therapeutic strategies tailored to the patient. Its success depends on establishing frameworks for regulating, compiling and interpreting key information. If this sounds like personalized medicine, it is—but more so. This presentation will discuss how to integrate clinical information with physiological, biochemical, and molecular laboratory studies to help define individual patterns of disease and potentially lead to better individual treatment.
An Update on Immune Thrombocytopenic Purpura (ITP): A New Treatment Paradigm, Terry B. Gernsheimer, MD
Treatment algorithms for ITP have not changed for the last decade, yet recent developments in treatment have created a paradigm shift in the management and understanding of this disease. This presentation will provide the latest information on the new thinking of the pathology of ITP, its impact on the management of ITP, and the integration of novel agents into therapeutic strategies.
Lymphoma, David G. Maloney, MD, PhD
Both autologous and allogeneic stem cell transplantation are viable treatment alternatives for the non-Hodgkin’s lymphomas. The decision as to which treatment to pursue is individualized based on the type of lymphoma, the stage of the disease and the general health of the patient. This presentation will discuss the treatment options that are available for non-Hodgkin’s lymphoma and address the prognostic indicators that influence outcomes.
Post Stem Cell Transplant, Paul V. O'Donnell, MD, PhD, FACP
Historically, the best results of allogeneic hematopoietic transplantation have occurred with an HLA-identical-sibling donor, but for patients who have not found a matching donor, alternative donor methods should be considered. These include two leading therapies, unrelated cord blood transplant or halploidentical transplant. This presentation will discuss how the selection of optimal alternative graft sources, mismatched unrelated donor, umbilical cord blood, or haploidentical transplant are determined, and the overall and long-term response rates to these treatment methods.
Surgical Oncology, David R. Byrd, MD, FACS
When metastatic disease is limited to an organ-specific site, an important consideration is whether the disease is resectable at the time of initial diagnosis or whether it is initially deemed to be unresectable but may become resectable with the up-front use of chemotherapy. With the integration of chemotherapy and surgical resection, overall five-year survival rates on the order of 30–40 percent can now be achieved. This presentation will explore the importance of a multidisciplinary, team-based approach and the role of surgeons, medical oncologists, radiologists, and other health care professionals in the treatment of cancer.
Hybrid Imaging: A New Era for Imaging Cancer Patients, Hubert Vesselle, MD, PhD
New hybrid imaging scanners combine either positron emission tomography (PET) or single photon emission computed tomography (SPECT) with traditional computed tomography (CT). The resulting hybrid scanners (PET/CT, SPECT/CT) allow both functional and anatomic imaging with great synergy for diagnosis of cancer and evaluation of tumor response to therapy.